Blume Capital Management Inc. Purchases 492 Shares of Hims & Hers Health, Inc. $HIMS

Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 35.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,874 shares of the company’s stock after buying an additional 492 shares during the period. Blume Capital Management Inc.’s holdings in Hims & Hers Health were worth $93,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in HIMS. Smartleaf Asset Management LLC boosted its position in shares of Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after acquiring an additional 227 shares in the last quarter. True Vision MN LLC lifted its stake in Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after purchasing an additional 328 shares during the period. Allworth Financial LP boosted its holdings in Hims & Hers Health by 20.0% during the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after purchasing an additional 334 shares in the last quarter. Signaturefd LLC grew its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after purchasing an additional 388 shares during the period. Finally, WealthPlan Investment Management LLC grew its stake in shares of Hims & Hers Health by 2.6% in the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after purchasing an additional 410 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $49.40 on Wednesday. The stock has a 50-day simple moving average of $51.07 and a 200 day simple moving average of $49.21. The stock has a market capitalization of $11.17 billion, a price-to-earnings ratio of 61.75, a P/E/G ratio of 3.50 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12-month low of $18.33 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the previous year, the business posted $0.06 EPS. The company’s revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the sale, the chief financial officer owned 128,984 shares in the company, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the completion of the transaction, the insider owned 297,139 shares in the company, valued at approximately $15,005,519.50. This represents a 4.42% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,434,306 shares of company stock worth $74,369,240. Company insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. KeyCorp started coverage on Hims & Hers Health in a report on Tuesday. They set a “sector weight” rating for the company. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Finally, Truist Financial reduced their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research report on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.